Actively Recruiting
Phase III Study of the Engineered Donor Graft Orca-Q for Children Undergoing Hematopoietic Cell Transplant for Blood Cancers
Led by University of Florida · Updated on 2026-10-30
40
Participants Needed
4
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase III study to evaluate the safety and effectiveness of an engineered donor graft called Orca-Q in children with blood cancers undergoing hematopoietic cell transplant HCT. This trial focuses on pediatric patients diagnosed with various leukemias and related hematologic malignancies. The study is sponsored by the University of Florida and aims to improve transplant outcomes using this novel biological product. Participants will receive Orca-Q, which includes Orca-Q Prime and Orca-Q Supplement, administered intravenously after they undergo a myeloablative conditioning regimen to prepare for transplant. The treatment involves a single group design where all enrolled patients receive the study graft. This trial includes both phase I and phase II portions and plans to follow participants through transplant and recovery. During the study, participants will be closely monitored for outcomes such as primary and secondary graft failure within 28 and 100 days, respectively. Additional assessments include survival rates, relapse rates, graft-versus-host disease incidence, infection rates, and adverse events up to two years post-transplant. The trial includes regular evaluations of blood counts, organ function, and overall health to assess the safety and efficacy of Orca-Q. Participation may last several months to years depending on follow-up schedules.
CONDITIONS
Brief Title
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
Research Team
A
Alex Leggett, MS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here